Each year in the UK, 30,000 children under the age of five are hospitalised with RSV and it causes around 30 infant deaths.

Babies born very prematurely will be offered protection against respiratory syncytial virus (RSV) with a long-acting antibody ...

1. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. The Lancet ...

Sanofi agreed to buy UK vaccine developer Vicebio Ltd. for as much as $1.6 billion, as it seeks to expand in respiratory ...

Vaccination of pregnant women has been linked to a drop in newborns being admitted to hospital with a serious lung infection, ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

Respiratory syncytial virus (RSV) is an infectious respiratory disease that can look and sound a lot like a cold, with coughing, sneezing and a runny nose. But RSV can turn serious and send some ...

In the first year of life, 65 per cent of babies get infected by Respiratory Syncytial Virus (RSV). This causes bronchiolitis, and is thought to kill nearly 200,000 children every year worldwide.

Respiratory syncytial virus is one of the leading causes of death for infants globally, and a safe vaccine is badly needed. ... Currently, treatment for RSV consists of monoclonal antibodies.

Respiratory syncytial virus (RSV) ... The aim of treatment is to make the child as comfortable as possible while the body’s immune system battles the infection.

STAFF WRITERS GIPPSLANDERS are being urged to protect themselves and their loved ones against flu and respiratory syncytial ...

Respiratory syncytial virus (RSV) is a leading viral cause of acute lower respiratory infections and associated deaths among infants and children worldwide, underlying an estimated 33.8 million ...